These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10650816)

  • 21. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
    Yang CC; Chu KC; Yeh WM
    Urol Oncol; 2004; 22(1):1-6. PubMed ID: 14969795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
    Inoue K; Kamada M; Slaton JW; Fukata S; Yoshikawa C; Tamboli P; Dinney CP; Shuin T
    Clin Cancer Res; 2002 Jun; 8(6):1863-70. PubMed ID: 12060629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.
    Adams J; Carder PJ; Downey S; Forbes MA; MacLennan K; Allgar V; Kaufman S; Hallam S; Bicknell R; Walker JJ; Cairnduff F; Selby PJ; Perren TJ; Lansdown M; Banks RE
    Cancer Res; 2000 Jun; 60(11):2898-905. PubMed ID: 10850435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer.
    Szarvas T; Jäger T; Tötsch M; vom Dorp F; Kempkensteffen C; Kovalszky I; Romics I; Ergün S; Rübben H
    Clin Cancer Res; 2008 Dec; 14(24):8253-62. PubMed ID: 19088043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
    Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
    BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlation of angiogenesis with expression of vascular endothelial growth factor and its receptors in lung carcinoma].
    Zhang G; Zhao M; Xu M; Yang Y; Wang M; Yang C
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Feb; 25(2):89-93. PubMed ID: 11953105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
    Lee SE; Chow NH; Chi YC; Tzai TS; Yang WH; Lin SN
    Anticancer Res; 1994; 14(3B):1317-24. PubMed ID: 7915094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression of ER beta protein correlates with vascular endothelial growth factor and its prognostic significance in human breast cancer.
    Wen XF; Shen Z; Shen ZZ; Nguyen M; Shao ZM
    Oncol Rep; 2002; 9(5):937-44. PubMed ID: 12168051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.
    Mineta H; Miura K; Ogino T; Takebayashi S; Misawa K; Ueda Y; Suzuki I; Dictor M; Borg A; Wennerberg J
    Br J Cancer; 2000 Sep; 83(6):775-81. PubMed ID: 10952783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR
    Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer.
    Bernardini S; Fauconnet S; Chabannes E; Henry PC; Adessi G; Bittard H
    J Urol; 2001 Oct; 166(4):1275-9. PubMed ID: 11547057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.
    Cascinu S; Staccioli MP; Gasparini G; Giordani P; Catalano V; Ghiselli R; Rossi C; Baldelli AM; Graziano F; Saba V; Muretto P; Catalano G
    Clin Cancer Res; 2000 Jul; 6(7):2803-7. PubMed ID: 10914727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
    Wu Y; Saldana L; Chillar R; Vadgama JV
    Int J Oncol; 2002 Mar; 20(3):509-16. PubMed ID: 11836562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
    Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
    Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer.
    Lennard CM; Patel A; Wilson J; Reinhardt B; Tuman C; Fenton C; Blair E; Francis GL; Tuttle RM
    Surgery; 2001 May; 129(5):552-8. PubMed ID: 11331447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.